ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
- Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
- These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain.
- ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry.
- We believe these findings will facilitate and expand dialogues with potential partners in the agriculture and animal health industries,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.